Journal of International Oncology››2018,Vol. 45››Issue (3): 129-133.doi:10.3760/cma.j.issn.1673-422X.2018.03.001
Ye Zhihua, Huang Geng, Fu Jinlun, Gui Dingwen
Received:
2017-09-11Online:
2018-03-08Published:
2018-05-16Contact:
Gui Dingwen E-mail:drguidingwen@163.comYe Zhihua, Huang Geng, Fu Jinlun, Gui Dingwen. Effects of miR-1291 on the cell cycle and proliferation of renal cell carcinoma by regulating the expression of Zinc finger protein 8 gene[J]. Journal of International Oncology, 2018, 45(3): 129-133.
[1] Shinohara N, Abe T. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma[J]. Int J Urol, 2015, 22(10): 888-897. DOI: 10.1111/iju.12858. [2] Cutruzzula P, Cahn D, Kivlin D, et al. A review of translocation T(6;11) renal cell carcinoma tumors in the adult patient[J]. Curr Urol, 2017, 10(2): 69-71. DOI: 10.1159/000447154. [3] Kanwal R, Plaga AR, Liu X, et al. MicroRNAs in prostate cancer: functional role as biomarkers[J]. Cancer Lett, 2017, 407: 9-20. DOI: 10.1016/j.canlet.2017.08.011. [4] Tu MJ, Pan YZ, Qiu JX, et al. MicroRNA-1291 targets the FOXA2AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis[J]. Oncotarget, 2016, 7(29): 45547-45561. DOI: 10.18632/oncotarget.9999. [5] Nakamura K, Sawada K, Yoshimura A, et al. Clinical relevance of circulating cellfree microRNAs in ovarian cancer[J]. Mol Cancer, 2016, 15(1): 48. DOI: 10.1186/s1294301605360. [6] Petros FG, Wallis CJD. The utility of microRNAs as biomarkers in predicting progression and survival in patients with clearcell renal cell carcinoma[J]. BJU Int, 2017, 120(3): 305307. DOI: 10.1111/bju.13931. [7] Bi HC, Pan YZ, Qiu JX, et al. Nmethylnicotinamide and nicotinamide Nmethyltransferase are associated with microRNA1291altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis[J]. Carcinogenesis, 2014, 35(10): 2264-2272. DOI: 10.1093/carcin/bgu174. [8] Luo H, Guo W, Wang F, et al. miR1291 targets mucin 1 inhibiting cell proliferation and invasion to promote cell apoptosis in esophageal squamous cell carcinoma[J]. Oncol Rep, 2015, 34(5): 2665-2673. DOI: 10.3892/or.2015.4206. [9] Tong D, Liu Q, Liu G, et al. The HIF/PHF8/AR axis promotes prostate cancer progression[J]. Oncogenesis, 2016, 5(12): e283. DOI: 10.1038/oncsis.2016.74. [10] Ma Q, Chen Z, Jia G, et al. The histone demethylase PHF8 promotes prostate cancer cell growth by activating the oncomiR miR125b[J]. Onco Targets Ther, 2015, 8: 1979-1988. DOI: 10.2147/OTT.S85443. [11] Wang Q, Ma S, Song N, et al. Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis[J]. J Clin Invest, 2016, 126(6): 2205-2220. DOI: 10.1172/JCI85747. [12] Sun L, Huang Y, Wei Q, et al. Cyclin ECDK2 protein phosphorylates plant homeodomain finger protein 8 (PHF8) and regulates its function in the cell cycle[J]. J Biol Chem, 2015, 290(7): 4075-4085. DOI: 10.1074/jbc.M114.602532. [13] Li X, Gong X, Chen J, et al. miR340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclinD1 and cyclinD2[J]. Biochem Biophys Res Commun, 2015, 460(3): 670-677. DOI: 10.1016/j.bbrc.2015.03.088. |
[1] | Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan.Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity, proliferation, and apoptosis of multiple myeloma cells[J]. Journal of International Oncology, 2024, 51(3): 129-136. |
[2] | Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190. |
[3] | Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation, migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519. |
[4] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[5] | Qian Weiwei, Xu Shen, Kong Qi.Differential diagnosis value of D-dimer before operation in renal oncocytoma and chromophobe renal cell carcinoma[J]. Journal of International Oncology, 2023, 50(10): 614-617. |
[6] | Lian Haiwei, Yang Shuorui, Liu Renzhong.Mechanism study on regulation of glioblastoma cell proliferation and apoptosis by sciadopitysin combined with CX-4945 through Notch1 pathway[J]. Journal of International Oncology, 2022, 49(6): 321-326. |
[7] | Wu Jiayi, Chen Keyu, Shao Xiying, Wang Xiaojia.Research progress on the mechanism of CDK4/6 inhibitors promoting antitumor immunity by regulating the immune microenvironment of triple negative breast cancer[J]. Journal of International Oncology, 2022, 49(6): 362-365. |
[8] | Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing.MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2[J]. Journal of International Oncology, 2022, 49(4): 193-198. |
[9] | Laibijiang Wusiman, Cao Bowei, Zhang Wenbin, Gao Hua.Effects of exogenous AGR2 on the proliferation and invasion abilities of colon cancer cells[J]. Journal of International Oncology, 2022, 49(2): 73-78. |
[10] | Jin Jiahui, Chen Cunhai, Ma Xuezhen.Effects of radiation-associated miRNA in radiotherapy for breast cancer[J]. Journal of International Oncology, 2022, 49(12): 735-738. |
[11] | Jing Wenjun, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhao Lili, Zhang Xue, Wei Hongmei.Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer[J]. Journal of International Oncology, 2022, 49(11): 681-686. |
[12] | Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin.Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis[J]. Journal of International Oncology, 2022, 49(1): 45-50. |
[13] | Hong Anlan, Cao Meng, Wang Yan, Fang Fang.Research progress on lncRNAs as members of ceRNA network in melanoma[J]. Journal of International Oncology, 2022, 49(1): 61-64. |
[14] | Zhang Yongli, Zhang Ruojia, Fan Huancai, Ge Luna, Wang Lin.TXNDC5-Prx2 axis regulates drug resistance of prostate cancer cells[J]. Journal of International Oncology, 2021, 48(8): 473-478. |
[15] | Liu Pei, Pu Jiaze, Huang Wen, Wang Fei.Expression differences of miR-200c, miR-19a and miR-155 in gefitinib sensitive and drug resistant NSCLC patients and their effects on prognosis[J]. Journal of International Oncology, 2021, 48(7): 409-414. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||